



Application of Peptide-Drug-Conjugates in the Treatment of Cancer and Microbial Infections

Guest Editors:

Dr. Toni Todorovski

Department of Experimental and Health Sciences, Pompeu Fabra University, 08003 Barcelona, Spain

Prof. Dr. Daniela Kalafatovic

Department of Biotechnology, University of Rijeka, Radmile Matejčić 2, 51000 Rijeka, Croatia

Prof. Dr. Michael A. Firer

Department of Chemical Engineering and Adelson School of Medicine, Ariel University, Ariel 4070000, Israel

Deadline for manuscript submissions:

closed (20 May 2023)

Message from the Guest Editors

Dear Colleagues,

According to the World Health Organization (WHO), antimicrobial resistance (AMR) is one of the top ten global public health threats that humanity is facing, while in 2019 cancer disease became the leading cause of death in the industrialized countries. PDC therapeutics combine one or more small drug molecules conjugated, most often, to a cell-penetrating peptide (CPP) either directly or through a biodegradable linker. This integration of two bioactive elements into a single entity often provides novel functionalities and improved bioavailability to treat conditions where conventional drugs are ineffective.

With this Special Issue we would like to provide readers with the latest developments and innovations in the design and synthesis of peptide–drug conjugates that are used to target various infectious diseases and cancers. Therefore, we are interested in articles related to new chemical and conjugation strategies for developing efficient antimicrobial and anticancer PDCs using in vitro models, in vivo trials and with possible application in the pharmaceutical industry.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma